Unable to find growth at home, Japanese companies are looking for it overseas. Private equity investors can be helpful in everything from execution to integration, provided they can prove their credentials
Takeda Pharmaceutical’s acquisition of Shire, which values the Ireland-headquartered multinational drugmaker at $79.7 billion, casts a long shadow over recent Japanese outbound M&A activity. From a private...
SeaLink Capital Partners has led a INR2 billion ($29 million) investment in Indian maternal and pediatric hospital chain Surya Children’s Medicare, providing an exit for OrbiMed Advisors.
Japan's governance reforms have given activist investors more leverage over underperforming companies. PE firms are well positioned to offer solutions to these targets in the form of carve-outs, privatizations, or partnerships
Chinese B2B pharmaceutical trading and education platform Yaoshibang has received RMB420 million ($65 million) in Series C funding across two tranches.
A group of VCs including China Growth Capital have agreed to invest $16 million in Ono, a China-based company that claims to be the creator of the first decentralized social network.